Article: Drug Terminates Paroxysmal Supraventricular Tachycardia With Fewer Side Effects.

2001 DEC 12 - (NewsRx.com & NewsRx.net) -- CV Therapeutics, Inc., announced the presentation of results from a retrospective analysis comparing the proarrhythmic effects of adenosine and CVT-510, a selective A1 adenosine receptor agonist.

Data from this analysis indicated that after termination of paroxysmal supraventricular tachycardia (PSVT), a type of atrial arrhythmia, with either adenosine or CVT-510, the use of CVT-510 was associated with fewer abnormal ventricular beats and fewer postarrhythmia pauses, or skipped heartbeats.

These data were presented November 12, 2001, at the 2001 Scientific Sessions of the American Heart Association held in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!